HABS-HD - Core C - Clinical Core

HABS-HD - 核心 C - 临床核心

• 批准号: 10708870
• 负责人: Sid E O'Bryant
• 金额: $ 1154.5万
• 依托单位: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708870
• 关键词: Adherence; Adult; African American population; Age; Agreement; Alzheimer' s Disease; Alzheimer' s disease related dementia; Ancillary Study; Back; Behavioral; Biological Markers; Blood specimen; Brain; Cataloging; Cerebrospinal Fluid; Clinical; Clinical Data; Cognitive; Collaborations; Collection; Communities; Community Relations; Consensus; Consent; Data; Data Collection; Diagnosis; Disparity; Educational Materials; Enrollment; Ensure; Ethnic Population; Family; Feedback; Focus Groups; Foundations; Goals; Health; Health Disparities Research; Health Personnel; Image; Informatics; Informed Consent; Infrastructure; Interview; Letters; Licensing; Magnetic Resonance Imaging; Measures; Medical; Mexican Americans; Modeling; Monitor; Multicultural Education; Neuropsychology; Not Hispanic or Latino; Parents; Participant; Persons; Population; Positron-Emission Tomography; Prevention strategy; Printing; Procedures; Process; Protocols documentation; Real-Time Systems; Research; Sampling; Spinal Puncture; Standardization; Time; Update; Visit; Work; aging brain; biobank; clinical diagnosis; cohort; electronic data capture system; future implementation; health disparity; health goals; informant; neuroimaging; novel; outreach; participant interview; precision medicine; programs; racial population; recruit; social culture; treatment strategy; virtual; web site

HABS-HD CLINICAL CORE (CORE C) ABSTRACT The long-term goal of the Health & Aging Brain Study – Health Disparities (HABS-HD) is to establish a population-specific informed precision medicine for novel treatment and prevention strategies for Alzheimer’s disease (AD) as called for in NIA AD+ADRD Milestone 1. The Clinical Core (Core C) will meet this goal by continuing to conduct all direct participant interviews, assessments, imaging, and other protocol components (parent study and/or ancillary studies). By the time of the initiation of the U19, the cohort will consist of 3,000 community-dwelling participants ages 50 and above (n=1,000 African Americans [AA], 1,000 Mexican Americans [MA], and 1,000 non-Hispanic whites [NHW]). Visit one (V1) and 24-month longitudinal V2 data will be available at initiation of the U19 among the MA and NHW participants with V1 data available for the AA participants. As part of this U19, we will continue 24-month assessments of the existing cohort as well as enroll an additional 1,500 participants (n=500 per racial/ethnic group; age 30-49) for a more comprehensive examination of AT(N) defined biomarkers across adulthood among the three largest racial/ethnic groups in the U.S. Core C is responsible for reviewing all data for assignment of research diagnoses (medical and cognitive) as well as providing feedback to participants, families and health care providers as part of our “give back” to the community as indicated during the informed consent process by the participant. The data collected by Core C will be crucial for all Projects and will also be made available to the scientific community via LONI. The Clinical Core Aims are as follows: Aim 1 (Data Capture): In collaboration with all Cores, continue to follow harmonized protocols for the collection, processing, cataloging, storage and distribution of demographic, clinical and imaging data in support of overall program goals. Aim 2 (CSF Substudy): Conduct cerebrospinal fluid (CSF) collection substudy. Aim 3 (Consensus Reviews and Feedback): Continue to conduct consensus reviews to ensure appropriate assignment of research-based clinical diagnoses (cognitive and medical) and provide feedback to participants, families and heath care providers as indicated during informed consent process. Aim 4 (Collaboration): Collaborate with Cores and Projects. Aim 5 (Brain Bank): Build foundation, community relations and infrastructure for future implementation of HABS-HD Brain Bank. Aim 6 (Cross-Study Comparisons): Work collaboratively with other AD+ADRD projects and programs for cross-study comparisons leveraging HABS-HD clinical data. In collaboration with the Administrative Core (Core A), work to ensure cross-study comparisons with ongoing initiatives such as ADNI, WHICAP, SOL/INCA, LEADS, ABC-DS, New IDEAS, ADCs and others.

HABS-HD临床核心（核心C）摘要 健康与衰老大脑研究的长期目标 - 健康差异（HABS-HD）是建立一个 特定于人群的知情精度医学，用于新型治疗和预防策略的阿尔茨海默氏症 NIA AD+ADRD里程碑所要求的疾病（AD）1。临床核心（核心C）将通过 继续进行所有直接参与者的访谈，评估，成像和其他协议组件 （家长研究和/或辅助研究）。到U19启动时，该队列将包括3,000 50岁及以上的社区居民参与者（n = 1,000名非裔美国人[AA]，1,000墨西哥 美国人[MA]和1,000名非西班牙裔白人[NHW]）。访问一个（V1）和24个月的纵向V2数据将 可在MA和NHW参与者中使用U19启动，并提供可用于AA的V1数据 参与者。作为U19的一部分，我们将继续对现有队列的24个月评估以及注册 更全面 检查AT（n）在成年的AT（n）定义的生物标志物 美国核心C负责审查所有用于分配研究诊断的数据（医学和认知） 以及向参与者，家庭和医疗保健提供者提供反馈，作为我们“回馈”的一部分 社区如参与的知情同意过程中所示。核心收集的数据 C对于所有项目至关重要，也将通过LONI向科学界提供。这 临床核心目的如下：AIM 1（数据捕获）：与所有核心合作，继续遵循 用于收集，处理，编目，存储和分布人口统计的协议协议， 临床和成像数据支持总体计划目标。 AIM 2（CSF ordudy）：进行脑脊 流体（CSF）收集物质。 AIM 3（共识评论和反馈）：继续达成共识 评论以确保适当分配基于研究的临床诊断（认知和医学）和 如知情同意书，向参与者，家庭和卫生护理提供者提供反馈 过程。 AIM 4（协作）：与核心和项目合作。 AIM 5（大脑银行）：建立基础， 用于未来实施HABS-HD Brain Bank的社区关系和基础设施。目标6（跨研究） 比较）：与其他AD+ADRD项目和计划合作进行跨研究 利用HABS-HD临床数据。与行政核心（核心A）合作，以确保 与正在进行的计划（例如ADNI，WHICAP，SOL/INCA，LEADS，ABC-DS，NEW）等跨研究比较 想法，ADC和其他人。